283 related articles for article (PubMed ID: 9826477)
21. Anti-tumor activity of the TRA-8 anti-DR5 antibody in combination with cisplatin in an ex vivo human cervical cancer model.
Kendrick JE; Straughn JM; Oliver PG; Wang W; Nan L; Grizzle WE; Stockard CR; Alvarez RD; Buchsbaum DJ
Gynecol Oncol; 2008 Mar; 108(3):591-7. PubMed ID: 18177927
[TBL] [Abstract][Full Text] [Related]
22. Effects of RSR13 and oxygen on the cytotoxicity of cisplatin and carboplatin to EMT6 mouse mammary tumor cells in vitro and in vivo.
Donnelly ET; Kelley M; Rockwell S
Cancer Chemother Pharmacol; 2004 Jan; 53(1):43-50. PubMed ID: 14574460
[TBL] [Abstract][Full Text] [Related]
23. Cytotoxicity of different platinum (II) analogues to human tumour cell lines in vitro and murine tumour in vivo alone or combined with electroporation.
Cemazar M; Pipan Z; Grabner S; Bukovec N; Sersa G
Anticancer Res; 2006; 26(3A):1997-2002. PubMed ID: 16827135
[TBL] [Abstract][Full Text] [Related]
24. [Predictive value of in vitro MTT assay chemosensitivity test of cytotoxic drug activity in cervical cancer].
Xiao Y; Li JD; Shi HL; Liu JH; Feng YL; Li MD
Ai Zheng; 2007 Apr; 26(4):386-9. PubMed ID: 17430657
[TBL] [Abstract][Full Text] [Related]
25. Cross-resistance of platinum derivatives in H-1R, a cisplatin-resistant cell line.
Negoro K; Yamano Y; Nakashima D; Saito K; Nakatani K; Shiiba M; Bukawa H; Yokoe H; Uzawa K; Wada T; Tanzawa H; Fujita S
Oncol Rep; 2009 Feb; 21(2):443-9. PubMed ID: 19148521
[TBL] [Abstract][Full Text] [Related]
26. Differential nephrotoxicity of cisplatin and a novel series of traditional Chinese medicine-platinum anticancer agents correlates with their chemical reactivity towards sulfur-containing nucleophiles.
To KK; Au-Yeung SC; Ho YP
Anticancer Drugs; 2006 Jul; 17(6):673-83. PubMed ID: 16917213
[TBL] [Abstract][Full Text] [Related]
27. [Development of carboplatin].
Tsukagoshi S
Gan To Kagaku Ryoho; 1990 Sep; 17(9):1949-58. PubMed ID: 2203318
[TBL] [Abstract][Full Text] [Related]
28. Platinum (II) complexes with stereochemically-defined thiepane dioxide diamine ligands as anticancer drugs.
Cerè V; Grossi L; Munari D; Pollicino S; Martelli L; Martelli M
Anticancer Res; 2006; 26(3A):1815-9. PubMed ID: 16827112
[TBL] [Abstract][Full Text] [Related]
29. Use of a toxicity factor to explain differences in nephrotoxicity and myelosuppression among the platinum antitumour derivatives cisplatin, carboplatin and nedaplatin in rats.
Hanada K; Asano K; Nishimura T; Chimata T; Matsuo Y; Tsuchiya M; Ogata H
J Pharm Pharmacol; 2008 Mar; 60(3):317-22. PubMed ID: 18284811
[TBL] [Abstract][Full Text] [Related]
30. Effectiveness of cis-platin and carboplatin in the chemotherapy of squamous cell carcinoma grown as multicellular spheroids.
Schwachöfer JH; Crooijmans RP; Hoogenhout J; Kal HB; Theeuwes AG
Anticancer Res; 1990; 10(3):805-11. PubMed ID: 2195988
[TBL] [Abstract][Full Text] [Related]
31. [Phase II clinical trial of nedaplatin in advanced non-small cell lung cancer].
Xu RH; Guan ZZ; Jiang WQ; Huang H; Hu XH; Xie WM; Li XG; Liu YL; Pan LX; Dai AD; Zhuang W; Zhang C; Ma ZY; Wang JH
Ai Zheng; 2002 Dec; 21(12):1354-8. PubMed ID: 12520747
[TBL] [Abstract][Full Text] [Related]
32. Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family).
Yonezawa A; Masuda S; Yokoo S; Katsura T; Inui K
J Pharmacol Exp Ther; 2006 Nov; 319(2):879-86. PubMed ID: 16914559
[TBL] [Abstract][Full Text] [Related]
33. Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer.
Rao GG; Rogers P; Drake RD; Nguyen P; Coleman RL
Gynecol Oncol; 2005 Jan; 96(1):168-72. PubMed ID: 15589596
[TBL] [Abstract][Full Text] [Related]
34. Mini-review: discovery and development of platinum complexes designed to circumvent cisplatin resistance.
Kelland LR; Sharp SY; O'Neill CF; Raynaud FI; Beale PJ; Judson IR
J Inorg Biochem; 1999 Oct; 77(1-2):111-5. PubMed ID: 10626362
[TBL] [Abstract][Full Text] [Related]
35. Synthesis and anticancer activity of [2-hydroxy-1,3-diaminopropane-kappa 2N,N'] platinum(II) complexes.
Liu W; Chen X; Xie M; Lou L; Ye Q; Yu Y; Hou S
J Inorg Biochem; 2008 Oct; 102(10):1942-6. PubMed ID: 18707762
[TBL] [Abstract][Full Text] [Related]
36. In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin.
Pendyala L; Creaven PJ
Cancer Res; 1993 Dec; 53(24):5970-6. PubMed ID: 8261411
[TBL] [Abstract][Full Text] [Related]
37. Interactions of thymidine, hyperthermia, and cis-diammine-1,1-cyclobutane dicarboxylate platinum (II) in human T-cell leukemia.
Cohen JD; Robins HI; Schmitt CL; Tanner MA
Cancer Res; 1989 Nov; 49(21):5805-9. PubMed ID: 2676150
[TBL] [Abstract][Full Text] [Related]
38. Comparison of human tumour cell responses to cisplatin and ZD0473 with and without irradiation.
Raaphorst GP; Yang DP; Li LF; Malone S
Anticancer Res; 2004; 24(2B):613-8. PubMed ID: 15161002
[TBL] [Abstract][Full Text] [Related]
39. Preclinical antitumor activity of the oral platinum analog satraplatin.
Wosikowski K; Lamphere L; Unteregger G; Jung V; Kaplan F; Xu JP; Rattel B; Caligiuri M
Cancer Chemother Pharmacol; 2007 Sep; 60(4):589-600. PubMed ID: 17541592
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics of low-dose nedaplatin and validation of AUC prediction in patients with non-small-cell lung carcinoma.
Niioka T; Uno T; Yasui-Furukori N; Takahata T; Shimizu M; Sugawara K; Tateishi T
Cancer Chemother Pharmacol; 2007 Apr; 59(5):575-80. PubMed ID: 16912889
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]